We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against Billionaire John Paulson’s other stocks with huge upside potential.
John Alfred Paulson is an American billionaire hedge fund manager who founded Paulson & Co. in 1994. It is a New York-based fund management firm that specializes in private equity and hedge funds. Paulson graduated as valedictorian of his class with a summa cum laude distinction in finance from NYU’s College of Business and Public Administration in 1978. He also pursued an MBA at Harvard Business School as a George F. Baker Scholar, which is a prestigious recognition awarded to the top 5% of his class. It’s supported by the Sidney J. Weinberg/Goldman Sachs scholarship, which he earned in 1980. With a client base of 20, the firm’s latest 13F filing for Q4 2024 revealed ~$1.65 billion in managed 13F securities and a top 10 holdings concentration of 98.55%.
The firm is known for its expertise in event-driven arbitrage strategies, such as merger arbitrage, bankruptcy reorganizations, and other corporate events. Paulson & Co. also pursues investments in distressed debt opportunities throughout the US and Western Europe, with the help of its strategic insights and extensive market experience. John Paulson is now also bullish on gold after 15 years and expects its price to reach ~$5,000 per ounce by 2028. He is the largest shareholder in Perpetua Resources. On April 29, Reuters reported that in a recent interview, Paulson reinforced that his conviction in gold is underpinned by the analysis of central bank buying trends and rising global trade tensions. He highlighted the inclination of central banks and individuals to seek stable stores of value now and suggested that gold will therefore enhance its global standing. Paulson believes that the Western confiscation of Russia’s foreign reserve holdings following the Ukraine invasion is one of the reasons behind the anticipated appreciation of gold prices.
Our Methodology
To compile the list of billionaire John Paulson’s 10 stocks with huge upside potential, we sifted through Q4 2024 13F filings of Paulson & Co. from Insider Monkey. From these filings, we checked each stock’s upside potential from CNN and ranked the stocks in ascending order of this upside potential. We have also added Paulson & Co.’s stake in each company and the hedge fund sentiment around each stock.
Note: All data was sourced on May 2.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A scientist examining the results of a Phase III clinical trial for non-alcoholic steatohepatitis.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Paulson & Co.’s Stake: $630 million
Number of Hedge Fund Holders: 40
Average Upside Potential as of May 2: 26.03%
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company that delivers novel therapeutics for metabolic dysfunction-associated steatohepatitis/MASH in the US. It offers Rezdiffra, which is a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Following its FDA approval in March 2024, Rezdiffra has shown a strong performance in treating F2-F3 MASH in the US market. In its first 12 months, the drug made $317 million in net sales and treated more than 17,000 patients who previously lacked approved treatment options. Q1 2025 reported $137 million in net sales, which was 33% sequentially. The number of patients actively on Rezdiffra grew from 11,800 at the end of Q4 2024 to over 17,000 by the end of Q1 2025.
Notably, 70% of the company’s top 6,000 target prescribers have already prescribed Rezdiffra within the first year of its launch, and ~50% of the total 14,000 target prescribers have done so. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is concentrating its disease and product education efforts on the 315,000 diagnosed F2-F3 MASH patients currently under the care of its target prescribers, of which only about 5% are currently being treated with Rezdiffra.
Overall, MDGL ranks 8th on our list of Billionaire John Paulson’s stocks with huge upside potential. While we acknowledge the growth potential of MDGL, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than MDGL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
